Cargando…
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
BACKGROUND: Immune checkpoint inhibitors have been demonstrated to improve overall survival. Atypical patterns of response have been reported, including dissociated response (DR). We evaluated the prevalence of DR. PATIENTS AND METHODS: Patients had to have a baseline computed tomography (CT) scan a...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602606/ https://www.ncbi.nlm.nih.gov/pubmed/34562258 http://dx.doi.org/10.1007/s40268-021-00362-3 |
_version_ | 1784601608576827392 |
---|---|
author | Vaflard, Pauline Paoletti, Xavier Servois, Vincent Tresca, Patricia Pons-Tostivint, Elvire Sablin, Marie-Paule Ricci, Francesco Loirat, Delphine Hescot, Ségolène Torossian, Nouritza Bello Roufai, Diana Kamal, Maud Borcoman, Edith Le Tourneau, Christophe |
author_facet | Vaflard, Pauline Paoletti, Xavier Servois, Vincent Tresca, Patricia Pons-Tostivint, Elvire Sablin, Marie-Paule Ricci, Francesco Loirat, Delphine Hescot, Ségolène Torossian, Nouritza Bello Roufai, Diana Kamal, Maud Borcoman, Edith Le Tourneau, Christophe |
author_sort | Vaflard, Pauline |
collection | PubMed |
description | BACKGROUND: Immune checkpoint inhibitors have been demonstrated to improve overall survival. Atypical patterns of response have been reported, including dissociated response (DR). We evaluated the prevalence of DR. PATIENTS AND METHODS: Patients had to have a baseline computed tomography (CT) scan and at least one follow-up CT scan and two target lesions (TLs). Three types of DR were evaluated using RECIST1.1: DR1, defined as at least one progressive and one responding TL; DR2, defined as at least one progressive and one stable TL; and DR3, defined as at least one stable and one responding TL. RESULTS: A total of 1244 measurements of 272 TLs were performed in 100 patients. Forty-nine out of the 272 TLs (18%) had received old or recent radiotherapy, and 42 (15%) had been biopsied. An objective response was observed in 22 patients (22%) and on 52 TLs (19%). DR1 were observed in 8% of patients. At the tumor measurement level, the response rate was lower in the case of prior radiotherapy (29% vs 34%, p = 0.01) and higher in the case of prior biopsy (40% vs 32%, p = 0.02). CONCLUSIONS: A DR was observed in 8% of patients. Response rate was lower in the case of prior radiotherapy and higher in the case of prior biopsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40268-021-00362-3. |
format | Online Article Text |
id | pubmed-8602606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-86026062021-12-02 Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy Vaflard, Pauline Paoletti, Xavier Servois, Vincent Tresca, Patricia Pons-Tostivint, Elvire Sablin, Marie-Paule Ricci, Francesco Loirat, Delphine Hescot, Ségolène Torossian, Nouritza Bello Roufai, Diana Kamal, Maud Borcoman, Edith Le Tourneau, Christophe Drugs R D Original Research Article BACKGROUND: Immune checkpoint inhibitors have been demonstrated to improve overall survival. Atypical patterns of response have been reported, including dissociated response (DR). We evaluated the prevalence of DR. PATIENTS AND METHODS: Patients had to have a baseline computed tomography (CT) scan and at least one follow-up CT scan and two target lesions (TLs). Three types of DR were evaluated using RECIST1.1: DR1, defined as at least one progressive and one responding TL; DR2, defined as at least one progressive and one stable TL; and DR3, defined as at least one stable and one responding TL. RESULTS: A total of 1244 measurements of 272 TLs were performed in 100 patients. Forty-nine out of the 272 TLs (18%) had received old or recent radiotherapy, and 42 (15%) had been biopsied. An objective response was observed in 22 patients (22%) and on 52 TLs (19%). DR1 were observed in 8% of patients. At the tumor measurement level, the response rate was lower in the case of prior radiotherapy (29% vs 34%, p = 0.01) and higher in the case of prior biopsy (40% vs 32%, p = 0.02). CONCLUSIONS: A DR was observed in 8% of patients. Response rate was lower in the case of prior radiotherapy and higher in the case of prior biopsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40268-021-00362-3. Springer International Publishing 2021-09-25 2021-12 /pmc/articles/PMC8602606/ /pubmed/34562258 http://dx.doi.org/10.1007/s40268-021-00362-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Article Vaflard, Pauline Paoletti, Xavier Servois, Vincent Tresca, Patricia Pons-Tostivint, Elvire Sablin, Marie-Paule Ricci, Francesco Loirat, Delphine Hescot, Ségolène Torossian, Nouritza Bello Roufai, Diana Kamal, Maud Borcoman, Edith Le Tourneau, Christophe Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy |
title | Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy |
title_full | Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy |
title_fullStr | Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy |
title_full_unstemmed | Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy |
title_short | Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy |
title_sort | dissociated responses in patients with metastatic solid tumors treated with immunotherapy |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602606/ https://www.ncbi.nlm.nih.gov/pubmed/34562258 http://dx.doi.org/10.1007/s40268-021-00362-3 |
work_keys_str_mv | AT vaflardpauline dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy AT paolettixavier dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy AT servoisvincent dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy AT trescapatricia dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy AT ponstostivintelvire dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy AT sablinmariepaule dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy AT riccifrancesco dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy AT loiratdelphine dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy AT hescotsegolene dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy AT torossiannouritza dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy AT belloroufaidiana dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy AT kamalmaud dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy AT borcomanedith dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy AT letourneauchristophe dissociatedresponsesinpatientswithmetastaticsolidtumorstreatedwithimmunotherapy |